Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Rating of “Moderate Buy” from Analysts

Posted by Brian Himes on Jul 27th, 2026

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report) have earned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $9.50.

SANA has been the topic of a number of research analyst reports. Wedbush lifted their price target on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Tuesday, April 14th. Weiss Ratings upgraded shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a report on Monday, May 11th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th.

Read Our Latest Report on SANA

Sana Biotechnology Stock Performance

Shares of SANA opened at $3.18 on Monday. The firm has a market cap of $884.96 million, a P/E ratio of -3.42 and a beta of 2.13. Sana Biotechnology has a 12 month low of $2.61 and a 12 month high of $6.55. The stock’s 50 day moving average is $3.26 and its two-hundred day moving average is $3.57.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. Equities research analysts forecast that Sana Biotechnology will post -0.59 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Xponance LLC boosted its holdings in Sana Biotechnology by 25.6% in the 4th quarter. Xponance LLC now owns 13,068 shares of the company’s stock worth $53,000 after buying an additional 2,662 shares during the last quarter. Creative Planning raised its holdings in shares of Sana Biotechnology by 5.3% during the third quarter. Creative Planning now owns 54,177 shares of the company’s stock valued at $192,000 after acquiring an additional 2,719 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Sana Biotechnology by 29.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,944 shares of the company’s stock valued at $53,000 after acquiring an additional 2,943 shares during the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of Sana Biotechnology by 74.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after acquiring an additional 4,088 shares in the last quarter. Finally, Polymer Capital Management US LLC lifted its position in shares of Sana Biotechnology by 32.5% in the fourth quarter. Polymer Capital Management US LLC now owns 18,285 shares of the company’s stock valued at $74,000 after acquiring an additional 4,480 shares in the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

About Sana Biotechnology

(Get Free Report)

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.